TY - JOUR
T1 - Immunotherapy for human papillomavirus-associated disease and cervical cancer
T2 - Review of clinical and translational research
AU - Lee, Sung Jong
AU - Yang, Andrew
AU - Wu, T. C.
AU - Hung, Chien Fu
N1 - Publisher Copyright:
© 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
PY - 2016/9
Y1 - 2016/9
N2 - Cervical cancer is the fourth most lethal women’s cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPVspecific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.
AB - Cervical cancer is the fourth most lethal women’s cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPVspecific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.
KW - Human Papillomavirus
KW - Immune Checkpoint Inhibitor
KW - Immunotherapy
KW - Therapeutics
KW - Uterine Cervical Neoplasms
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84978422164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978422164&partnerID=8YFLogxK
U2 - 10.3802/jgo.2016.27.e51
DO - 10.3802/jgo.2016.27.e51
M3 - Review article
C2 - 27329199
AN - SCOPUS:84978422164
SN - 2005-0380
VL - 27
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 5
M1 - e51
ER -